Systemic antipsoriatic therapy may mitigate CCVD risk in patients with psoriasis

In a recent study, researchers have found that systemic antipsoriatic therapy could reduce cardio-cerebrovascular disease (CCVD) development in patients with a history of psoriasis.

There needs to be more data on the effect of antipsoriatic therapy on CCVD. In the present study, researchers performed a population-based nested case–control study to investigate the impact of systemic antipsoriatic therapy on CCVD in patients with psoriasis.

They used nationwide cohort data from the Korean National Health Insurance Claims database. With data, they identified newly diagnosed cases of psoriasis patients. The incidence of CCVD events (ischemic heart disease, myocardial infarction, cerebral infarction, and cerebral haemorrhage) was examined in the enrolled participants after enrollment.

They determined the proportion of the study period during which patients received systemic antipsoriatic therapy. PTP % was the sum of all therapy duration with systemic antipsoriatic drugs divided by the total observation period.

The critical points of the study are:

• In the CCVD group, among 251 813 participants, CCVD events were experienced by 6262 participants.
• Controls included 245 551 patients without CCVD history (non-CCVD group).
• Researchers found greater PTP in the non-CCVD group than in the CCVD group.
• As recorded in multiple logistic regression analysis, PTP was inversely associated with the CCVD risk following adjustment for age, sex, diabetes, hypertension, and dyslipidemia.
• A 10% increase in PTP reduced CCVD risk by 0.96.
• Reduced CCVD risk was robust for both conventional antipsoriatic therapy and biologics.

They said, “In our study, systemic antipsoriatic therapy was inversely associated with CCVD risk in psoriasis patients.”

The study highlighted that systemic antipsoriatic therapy could reduce CCVD development in psoriatic patients.

Further reading:

https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.16904